127 related articles for article (PubMed ID: 38539510)
1. Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Guberina M; Pöttgen C; Guberina N; Hoffmann C; Wiesweg M; Richlitzki C; Metzenmacher M; Aigner C; Bölükbas S; Gauler T; Eberhardt WEE; Forsting M; Herrmann K; Theegarten D; Darwiche K; Jendrossek V; Stuschke M; Schuler M
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539510
[No Abstract] [Full Text] [Related]
2. Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.
Guberina N; Pöttgen C; Schuler M; Guberina M; Stamatis G; Plönes T; Metzenmacher M; Theegarten D; Gauler T; Darwiche K; Aigner C; Eberhardt WEE; Stuschke M
Radiat Oncol; 2022 Jul; 17(1):126. PubMed ID: 35842712
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
4. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
5. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
7. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
[TBL] [Abstract][Full Text] [Related]
8. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
10. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Valentini V; Coco C; Picciocchi A; Morganti AG; Trodella L; Ciabattoni A; Cellini F; Barbaro B; Cogliandolo S; Nuzzo G; Doglietto GB; Ambesi-Impiombato F; Cosimelli M
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):664-74. PubMed ID: 12062610
[TBL] [Abstract][Full Text] [Related]
11. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
[TBL] [Abstract][Full Text] [Related]
13. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
Guberina N; Pöttgen C; Schuler M; Guberina M; Stamatis G; Plönes T; Krebs B; Metzenmacher M; Theegarten D; Gauler T; Jöckel KH; Darwiche K; Aigner C; Stuschke M; Eberhardt WE
Eur J Cancer; 2020 Oct; 138():156-168. PubMed ID: 32889370
[TBL] [Abstract][Full Text] [Related]
14. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence.
Pöttgen C; Eberhardt W; Stamatis G; Stuschke M
Oncotarget; 2017 Jun; 8(25):41670-41678. PubMed ID: 28415831
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
17. Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution.
Yegya-Raman N; Aisner J; Kim S; Sayan M; Li D; Langenfeld J; Patel M; Malhotra J; Jabbour SK
Adv Radiat Oncol; 2019; 4(3):541-550. PubMed ID: 31360811
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.
Vyfhuis MAL; Bhooshan N; Burrows WM; Turner M; Suntharalingam M; Donahue J; Nichols EM; Feliciano J; Bentzen SM; Badiyan S; Carr SR; Friedberg J; Simone CB; Edelman MJ; Feigenberg SJ; Mohindra P
Adv Radiat Oncol; 2017; 2(3):259-269. PubMed ID: 29114590
[TBL] [Abstract][Full Text] [Related]
19. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
20. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer.
Kroese TE; Buijs GS; Burger MDL; Ruurda JP; Mook S; Brosens LAA; van Rossum PSN; van Hillegersberg R
Ann Surg Oncol; 2022 Aug; 29(8):4848-4857. PubMed ID: 35381938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
